EDWARDS LIFESCIENCES CORP

ISIN: US28176E1082 WKN: 28176E108 Asset Class: Stock



Company Profile

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	22	20	21
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	4,035,700,000		3,095,800,000		3,180,700,000	
Common stock capital		650,500,000		646,300,000		642,000,000
Fixed assets	5,327,500,000		5,196,700,000		5,321,900,000	
Equity capital of a company		6,719,400,000		5,806,700,000		5,835,900,000
Cash and cash equivalents	1,147,300,000		769,500,000		864,300,000	
Accrued liabilities		433,500,000		410,500,000		450,300,000
Other assets	-		-		-	
Current liabilities		1,195,400,000		1,022,400,000		1,032,300,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,448,400,000		1,463,400,000		1,634,400,000
Different income		-		-		-
Other liabilities		344,900,000		387,100,000		519,300,000
Total assets	9,363,200,000	9,363,200,000	8,292,500,000	8,292,500,000	8,502,600,000	8,502,600,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	19,800	17,300	15,700
Equity ratio	72.51%	70.02%	68.64%
Debt-equity ratio	37.92%	42.81%	45.69%

Others

	2023	2022	2021
Tax Expense Rate	12.43%	13.89%	11.69%

EDWARDS LIFESCIENCES CORP

ISIN: US28176E1082 WKN: 28176E108 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	6,004,800,000	5,382,400,000	5,232,500,000
Net income	1,402,400,000	1,521,900,000	1,503,100,000
EBIT	1,431,279,080	1,617,803,620	1,572,989,880
Operating income before taxes	1,598,100,000	1,767,400,000	1,702,000,000
Cash Flow	895,800,000	1,218,200,000	1,732,100,000
Net interest income	42,700,000	9,300,000	-7,400,000
Research and development expenses	1,071,800,000	945,200,000	903,100,000
Income taxes	198,700,000	245,500,000	198,900,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	279,072	286,294	306,684

Board of Directors

Members of Management Board

Nicholas Valeriani	Chairman of Board of Directors
Kieran Gallahue	Member of Board of Directors
Leslie Davis	Member of Board of Directors
Leslie Heisz	Member of Board of Directors
Paul LaViolette	Member of Board of Directors
Ramona Sequeira	Member of Board of Directors
Steven Loranger	Member of Board of Directors
Arnold A. Pinkston	Member of Executive Committee
Bernard J. Zovighian	Member of Executive Committee
Catherine M. Szyman	Member of Executive Committee
Christine Z. McCauley	Member of Executive Committee
Daveen Chopra	Member of Executive Committee
Dirksen J. Lehman	Member of Executive Committee
Donald E. Bobo, Jr.	Member of Executive Committee
Gary I. Sorsher	Member of Executive Committee
Jean-Luc Lemercier	Member of Executive Committee
Joseph Nuzzolese	Member of Executive Committee
Larry L. Wood	Member of Executive Committee
Scott B. Ullem	Member of Executive Committee
Todd J. Brinton	Member of Executive Committee
Wayne Markowitz	Member of Executive Committee